Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

The main reason for liver-related death globally is reported as cancer which results in most patients with cirrhosis, therefore in this article, we discuss the epidemiology of liver diseases and liver cancer in the world.

Ongoing review article efforts to address updated knowledge of study topics worldwide. Information on the prevalence and mortality of liver disease were extracted from Pubmed, Scopus, Web of Science and Cochrane Library. Ninety-two relevant in-depth consequent guide approaches and evidence-based choices were selected, associated with a knowledgeable collection of current, high-quality manuscripts.

Research reported that around 2.3 billion people in the world are infected with one of the hepatitis viruses that could cause liver cancer. The prevalence of non-alcoholic fatty liver disease, cirrhosis and liver cancer is varied worldwide. In the United States, each year 18600 males and 9000 females die from liver cancer. The global burden of deaths due to liver cancer was reported in 830,200 in 2020 that predicted to increase to >55% by 2040. The major causes of liver cancer reported as hepatitis B (mainly in Asia) and C viruses. Regarding chronic liver disease that could cause cancer in some patients, the prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 6% to 35% worldwide. Steatosis and steatohepatitis affect 25% of the population worldwide. It is well known that the geographic distribution of different forms of liver disorders is divergent. Owing to population growth and ageing, liver cirrhosis and its development of cancer is an important health subject worldwide. Further studies regarding early detection of liver disease based on the easy and inexpensive test to score primary necroinflammation recommended advantageously.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882271605231211102803
2024-04-19
2025-01-19

  • From This Site

    /content/journals/nemj/10.2174/0102506882271605231211102803
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882271605.html?itemId=/content/journals/nemj/10.2174/0102506882271605231211102803&mimeType=html&fmt=ahah

References

  1. VerrasG.I. MulitaF. PouwelsS. ParmarC. DrakosN. BouchagierK. KaplanisC. SkroubisG. Outcomes at 10-Year follow-up after roux-en-y gastric bypass, biliopancreatic diversion, and sleeve gastrectomy.J. Clin. Med.20231215497310.3390/jcm1215497337568375
     [Google Scholar]
  2. MulitaF. LampropoulosC. KehagiasD. VerrasG.I. TchabashviliL. KaplanisC. LiolisE. IliopoulosF. PerdikarisI. KehagiasI. Long-term nutritional deficiencies following sleeve gastrectomy: A 6-year single-centre retrospective study.Przegl. Menopauz.202120417017610.5114/pm.2021.11095435069068
     [Google Scholar]
  3. ZhangC. LiuS. YangM. Hepatocellular carcinoma and obesity, type 2 diabetes mellitus, cardiovascular disease: Causing factors, molecular links, and treatment options.Front. Endocrinol.20211280852610.3389/fendo.2021.80852635002979
     [Google Scholar]
  4. SaittaC. PollicinoT. RaimondoG. Obesity and liver cancer.Ann. Hepatol.201918681081510.1016/j.aohep.2019.07.00431543467
     [Google Scholar]
  5. GuptaA. DasA. MajumderK. AroraN. MayoH.G. SinghP.P. BegM.S. SinghS. Obesity is independently associated with increased risk of hepatocellular cancer–related mortality.Am. J. Clin. Oncol.201841987488110.1097/COC.000000000000038828537989
     [Google Scholar]
  6. PhilipsC.A. RajeshS. NairD.C. AhamedR. AbduljaleelJ.K. AugustineP. Hepatocellular carcinoma in 2021: An exhaustive update.Cureus20211311e1927410.7759/cureus.1927434754704
     [Google Scholar]
  7. ChenJ.G. ZhuJ. ZhangY.H. ChenY.S. LuJ.H. ZhuY.R. ChenH.Z. ShenA.G. WangG.R. GroopmanJ.D. KenslerT.W. Liver cancer mortality over six decades in an epidemic area: What we have learned.PeerJ20219e1060010.7717/peerj.1060033604165
     [Google Scholar]
  8. ArmengolC. SarriasM.R. SalaM. Hepatocellular carcinoma: Present and future.Med. Clin.20181501039039710.1016/j.medcli.2017.08.01029096967
     [Google Scholar]
  9. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  10. TianG. YangS. YuanJ. ThreapletonD. ZhaoQ. ChenF. CaoH. JiangT. LiL. Comparative efficacy of treatment strategies for hepatocellular carcinoma: Systematic review and network meta-analysis.BMJ Open2018810e02126910.1136/bmjopen‑2017‑02126930341113
     [Google Scholar]
  11. GaoE. HercunJ. HellerT. VilarinhoS. Undiagnosed liver diseases.Transl. Gastroenterol. Hepatol.202162810.21037/tgh.2020.04.0433824932
     [Google Scholar]
  12. AsraniS.K. DevarbhaviH. EatonJ. KamathP.S. Burden of liver diseases in the world.J. Hepatol.201970115117110.1016/j.jhep.2018.09.01430266282
     [Google Scholar]
  13. MokdadA.A. LopezA.D. ShahrazS. LozanoR. MokdadA.H. StanawayJ. MurrayC.J.L. NaghaviM. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis.BMC Med.201412114510.1186/s12916‑014‑0145‑y25242656
     [Google Scholar]
  14. MokdadA.H. ForouzanfarM.H. DaoudF. MokdadA.A. El BcheraouiC. Moradi-LakehM. KyuH.H. BarberR.M. WagnerJ. CercyK. KravitzH. CoggeshallM. ChewA. O’RourkeK.F. SteinerC. TuffahaM. ChararaR. Al-GhamdiE.A. AdiY. AfifiR.A. AlahmadiH. AlBuhairanF. AllenN. AlMazroaM. Al-NehmiA.A. AlRayessZ. AroraM. AzzopardiP. BarrosoC. BasulaimanM. BhuttaZ.A. BonellC. BreinbauerC. DegenhardtL. DennoD. FangJ. FatusiA. FeiglA.B. KakumaR. KaramN. KennedyE. KhojaT.A.M. MaaloufF. ObermeyerC.M. MattooA. McGovernT. MemishZ.A. MensahG.A. PatelV. PetroniS. ReavleyN. ZertucheD.R. SaeediM. SantelliJ. SawyerS.M. SsewamalaF. TaiwoK. TantawyM. VinerR.M. WaldfogelJ. ZuñigaM.P. NaghaviM. WangH. VosT. LopezA.D. Al RabeeahA.A. PattonG.C. MurrayC.J.L. Global burden of diseases, injuries, and risk factors for young people’s health during 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013.Lancet2016387100362383240110.1016/S0140‑6736(16)00648‑627174305
     [Google Scholar]
  15. BesteL.A. LeipertzS.L. GreenP.K. DominitzJ.A. RossD. IoannouG.N. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.Gastroenterology2015149614711482.e510.1053/j.gastro.2015.07.05626255044
     [Google Scholar]
  16. MitraS. DeA. ChowdhuryA. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl. Gastroenterol. Hepatol.202051610.21037/tgh.2019.09.0832258520
     [Google Scholar]
  17. SarinS.K. KumarM. EslamM. GeorgeJ. Al MahtabM. AkbarS.M.F. JiaJ. TianQ. AggarwalR. MuljonoD.H. OmataM. OokaY. HanK.H. LeeH.W. JafriW. ButtA.S. ChongC.H. LimS.G. PwuR.F. ChenD.S. Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission.Lancet Gastroenterol. Hepatol.20205216722810.1016/S2468‑1253(19)30342‑531852635
     [Google Scholar]
  18. RehmJ. MathersC. PopovaS. ThavorncharoensapM. TeerawattananonY. PatraJ. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders.Lancet200937396822223223310.1016/S0140‑6736(09)60746‑719560604
     [Google Scholar]
  19. Alves-BezerraM. CohenD.E. Triglyceride metabolism in the liver.Compr. Physiol.2017811810.1002/cphy.c17001229357123
     [Google Scholar]
  20. WangF.S. FanJ.G. ZhangZ. GaoB. WangH.Y. The global burden of liver disease: The major impact of China.Hepatology20146062099210810.1002/hep.2740625164003
     [Google Scholar]
  21. BrowningJ.D. SzczepaniakL.S. DobbinsR. NurembergP. HortonJ.D. CohenJ.C. GrundyS.M. HobbsH.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity.Hepatology20044061387139510.1002/hep.2046615565570
     [Google Scholar]
  22. CheemerlaS. BalakrishnanM. Global epidemiology of chronic liver disease.Clin. Liver Dis.202117536537010.1002/cld.106134136143
     [Google Scholar]
  23. PaikJ.M. GolabiP. BiswasR. AlqahtaniS. VenkatesanC. YounossiZ.M. Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the united states.Hepatol. Commun.20204689090310.1002/hep4.151032490324
     [Google Scholar]
  24. MoonA.M. SingalA.G. TapperE.B. Contemporary epidemiology of chronic liver disease and cirrhosis.Clin. Gastroenterol. Hepatol.202018122650266610.1016/j.cgh.2019.07.06031401364
     [Google Scholar]
  25. TapperEB ParikhND Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: Observational study.BMJ2018362k2817
     [Google Scholar]
  26. EstesC. RazaviH. LoombaR. YounossiZ. SanyalA.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology201867112313310.1002/hep.2946628802062
     [Google Scholar]
  27. WhiteD.L. ThriftA.P. KanwalF. DavilaJ. El-SeragH.B. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012.Gastroenterology20171524812820.e510.1053/j.gastro.2016.11.02027889576
     [Google Scholar]
  28. DasguptaP. HenshawC. YouldenD.R. ClarkP.J. AitkenJ.F. BaadeP.D. Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis.Front. Oncol.20201017110.3389/fonc.2020.0017132185125
     [Google Scholar]
  29. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.BMJ202137271n7110.1136/bmj.n7133782057
     [Google Scholar]
  30. YoungS. TariqR. ProvenzaJ. SatapathyS.K. FaisalK. ChoudhryA. FriedmanS.L. SingalA.K. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta‐analysis.Hepatol. Commun.20204795397210.1002/hep4.151932626829
     [Google Scholar]
  31. LinL. YanL. LiuY. QuC. NiJ. LiH. The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global regional, nationalage and sex level results from the global burden of disease study 2017.Liver Cancer20209556358210.1159/00050856833083281
     [Google Scholar]
  32. GazelakisK. MajeedA. KempW. Di MuzioB. GerstenmaierJ. CheungW. RobertsS.K. Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis.Sci. Rep.20211112095410.1038/s41598‑021‑00474‑534697374
     [Google Scholar]
  33. FerlayJ. ColombetM. SoerjomataramI. MathersC. ParkinD.M. PiñerosM. ZnaorA. BrayF. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int. J. Cancer201914481941195310.1002/ijc.3193730350310
     [Google Scholar]
  34. Global Cancer Observatory Lyon, FranceInternational Agency for Research on Cancer2018Available from: http://gco.iarc.fr/today/ Accessed: November 22, 2018
  35. PetrickJ.L. McGlynnK.A. The changing epidemiology of primary liver cancer.Curr. Epidemiol. Rep.20196210411110.1007/s40471‑019‑00188‑331259140
     [Google Scholar]
  36. Recio-BoilesA BabikerHM LotfollahzadehS Liver Cancer. StatPearlsStatPearls PublishingTreasure Island (FL)2023Available from: https://www.ncbi.nlm.nih.gov/books/NBK448337/
     [Google Scholar]
  37. PuustinenL. Barner-RasmussenN. PukkalaE. FärkkiläM. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland.Dig. Liver Dis.20195191294129910.1016/j.dld.2019.01.01530850346
     [Google Scholar]
  38. RumgayH. ArnoldM. FerlayJ. LesiO. CabasagC.J. VignatJ. LaversanneM. McGlynnK.A. SoerjomataramI. Global burden of primary liver cancer in 2020 and predictions to 2040.J. Hepatol.20227761598160610.1016/j.jhep.2022.08.02136208844
     [Google Scholar]
  39. ZhangY. TohL. LauP. WangX. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer.J. Biol. Chem.201228739324943251110.1074/jbc.M112.36828222854964
     [Google Scholar]
  40. RamleeM. WangJ. TohW. LiS. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene.Genes2016785010.3390/genes708005027548225
     [Google Scholar]
  41. LinkT. IwakumaT. Roles of p53 in extrinsic factor-induced liver carcinogenesis.Hepatoma Res.2017369510410.20517/2394‑5079.2017.0730123836
     [Google Scholar]
  42. XuC. XuZ. ZhangY. EvertM. CalvisiD.F. ChenX. β-Catenin signaling in hepatocellular carcinoma.J. Clin. Invest.20221324e15451510.1172/JCI15451535166233
     [Google Scholar]
  43. ZhangQ. YanH.B. WangJ. CuiS.J. WangX.Q. JiangY.H. FengL. YangP.Y. LiuF. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.Oncotarget2016729461274614110.18632/oncotarget.1006027323812
     [Google Scholar]
  44. MemonN. WeinbergerB.I. HegyiT. AleksunesL.M. Inherited disorders of bilirubin clearance.Pediatr. Res.201679337838610.1038/pr.2015.24726595536
     [Google Scholar]
  45. BhandariJ PawanK. StatPearlsTreasure Island (FL)StatPearls Publishing2021Available from: https://www.ncbi.nlm.nih.gov/books/NBK562171/
     [Google Scholar]
  46. RadlovićN. Hereditary hyperbilirubinemias.Srp. Arh. Celok. Lek.20141423-425726010.2298/SARH1404257R24839786
     [Google Scholar]
  47. JefferiesM. RauffB. RashidH. LamT. RafiqS. Update on global epidemiology of viral hepatitis and preventive strategies.World J. Clin. Cases201861358959910.12998/wjcc.v6.i13.58930430114
     [Google Scholar]
  48. CoveyA.M. Hepatocellular carcinoma: Updates to screening and diagnosis.J. Natl. Compr. Canc. Netw.2018165S66366510.6004/jnccn.2018.005229784751
     [Google Scholar]
  49. WongM.C.S. HuangJ.L.W. GeorgeJ. HuangJ. LeungC. EslamM. ChanH.L.Y. NgS.C. The changing epidemiology of liver diseases in the asia–pacific region.Nat. Rev. Gastroenterol. Hepatol.2019161577310.1038/s41575‑018‑0055‑030158570
     [Google Scholar]
  50. PerumpailB.J. KhanM.A. YooE.R. CholankerilG. KimD. AhmedA. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J. Gastroenterol.201723478263827610.3748/wjg.v23.i47.826329307986
     [Google Scholar]
  51. PaikJ.M. HenryL. De AvilaL. YounossiE. RacilaA. YounossiZ.M. Mortality related to nonalcoholic fatty liver disease is increasing in the united states.Hepatol. Commun.20193111459147110.1002/hep4.141931701070
     [Google Scholar]
  52. FeldJ.J. HeathcoteE.J. Epidemiology of autoimmune liver disease.J. Gastroenterol. Hepatol.200318101118112810.1046/j.1440‑1746.2003.03165.x12974897
     [Google Scholar]
  53. DalekosG.N. GatselisN.K. ZachouK. KoukoulisG.K. NAFLD and autoimmune hepatitis: Do not judge a book by its cover.Eur. J. Intern. Med.2020751910.1016/j.ejim.2020.02.00132051092
     [Google Scholar]
  54. ToyE. BalasubramanianS. SelmiC. LiC.S. BowlusC.L. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population.BMC Gastroenterol.20111118310.1186/1471‑230X‑11‑8321767410
     [Google Scholar]
  55. VeithM. TuffersJ PeycheyE KlemmerA KotkeV The distribution of alpha-1 antitrypsin genotypes between patients with COPD/Emphysema, Asthma and Bronchiectasis.Int J Chron Obstruct Pulmon Dis20201528272836
     [Google Scholar]
  56. SandahlT.D. LaursenT.L. MunkD.E. VilstrupH. WeissK.H. OttP. The prevalence of Wilson’s disease: An update.Hepatology202071272273210.1002/hep.3091131449670
     [Google Scholar]
  57. GuillaudO. DumortierJ. Couchonnal-BedoyaE. RuizM. Wilson disease and alpha1-antitrypsin deficiency: A review of non-invasive diagnostic tests.Diagnostics202313225610.3390/diagnostics1302025636673066
     [Google Scholar]
  58. BrodeS.K. LingS.C. ChapmanK.R. Alpha-1 antitrypsin deficiency: A commonly overlooked cause of lung disease: Figure 1.CMAJ2012184121365137110.1503/cmaj.11174922761482
     [Google Scholar]
  59. FabrellasN. HernándezR. GrauperaI. SolàE. RamosP. MartínN. SáezG. SimónC. PérezA. GraellT. LarrañagaA. GarciaM. de la AradaA. JuanolaA. CoidurasA. DuasoI. CasadoA. MartinJ. GinèsM. MorenoN. Gema PerezA. MartiL. BernatM. SolaM. OlivéC. SoléC. GinèsP. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.PLoS One2018139e020065610.1371/journal.pone.020065630226889
     [Google Scholar]
  60. OrciL.A. Sanduzzi-ZamparelliM. CaballolB. SapenaV. ColucciN. TorresF. BruixJ. ReigM. TosoC. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression.Clin. Gastroenterol. Hepatol.2022202283292.e1010.1016/j.cgh.2021.05.00233965578
     [Google Scholar]
  61. KoH.H. YoshidaE. Acute fatty liver of pregnancy.Can. J. Gastroenterol.2006201253010.1155/2006/63813116432556
     [Google Scholar]
  62. ArkemaE.V. CozierY.C. Epidemiology of sarcoidosis: Current findings and future directions.Ther. Adv. Chronic Dis.201891122724010.1177/204062231879019730364496
     [Google Scholar]
  63. QuockT.P. YanT. ChangE. GuthrieS. BroderM.S. Epidemiology of AL amyloidosis: A real-world study using US claims data.Blood Adv.20182101046105310.1182/bloodadvances.201801640229748430
     [Google Scholar]
  64. StoneWL BasitH AdilA Glycogen Storage DiseaseTreasure Island (FL)StatPearls Publishing2021
     [Google Scholar]
  65. SinghP. AroraA. StrandT.A. LefflerD.A. CatassiC. GreenP.H. KellyC.P. AhujaV. MakhariaG.K. Global prevalence of celiac disease: Systematic review and meta-analysis.Clin. Gastroenterol. Hepatol.2018166823836.e210.1016/j.cgh.2017.06.03729551598
     [Google Scholar]
  66. HopkinsP.C. YazigiN. NylundC.M. Incidence of biliary atresia and timing of hepatoportoenterostomy in the united states.J. Pediatr.201718725325710.1016/j.jpeds.2017.05.00628746031
     [Google Scholar]
  67. SuhJ.I. Drug-induced liver injury.Yeungnam Univ. J. Med.202037121210.12701/yujm.2019.0029731661757
     [Google Scholar]
  68. LiY. De StefanoV. LiH. ZhengK. BaiZ. GuoX. QiX. Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis.Clin. Res. Hepatol. Gastroenterol.201943446847410.1016/j.clinre.2018.10.01430528513
     [Google Scholar]
  69. ShojaieL. IorgaA. DaraL. Cell death in liver diseases: A review.Int. J. Mol. Sci.20202124968210.3390/ijms2124968233353156
     [Google Scholar]
  70. WangH. MehalW. NagyL.E. RotmanY. Immunological mechanisms and therapeutic targets of fatty liver diseases.Cell. Mol. Immunol.2021181739110.1038/s41423‑020‑00579‑333268887
     [Google Scholar]
  71. GDB 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017.The Lancet Gastroenterology Hepatology.202053245266
     [Google Scholar]
  72. SepanlouS.G. MalekzadehF. NaghaviM. ForouzanfarM.H. ShahrazS. Moradi-LakehM. MalekzadehR. PoustchiH. Trend of gastrointestinal and liver diseases in Iran: Results of the global burden of disease study, 2010.Middle East J. Dig. Dis.2015712113726396715
     [Google Scholar]
  73. HajarizadehB. Razavi-ShearerD. MeratS. AlavianS.M. MalekzadehR. RazaviH. Liver disease burden of hepatitis C virus infection in iran and the potential impact of various treatment strategies on the disease burden.Hepat. Mon.2016167e3723410.5812/hepatmon.3723427642346
     [Google Scholar]
  74. MohammadEbrahim Ghamar Chehreh VahediMohsen PourhoseingholiMohammad Amin AshtariSara KhedmatHossein AminMohsen ZaliMohammad Reza AlavianSeyed Moayed Estimation of diagnosis and treatment costs of non-alcoholic fatty liver disease: A two-year observation.Hepat Mon2013135e738210.5812/hepatmon.7382
     [Google Scholar]
  75. GhamariZ.T. TadayonF. MazdakH. Prevalence of liver cancer in Isfahan province, Iran.Indonesian Journal of Cancer2018122565910.33371/ijoc.v12i2.578
     [Google Scholar]
  76. MazdakH. Tolou GhamariZ. GholampourM. Bladder cancer: Total antioxidant capacity and pharmacotherapy with vitamin-E.Int. Urol. Nephrol.20205271255126010.1007/s11255‑020‑02411‑332088809
     [Google Scholar]
  77. TaherkhaniR. FarshadpourF. Epidemiology of hepatitis C virus in Iran.World J. Gastroenterol.20152138107901081010.3748/wjg.v21.i38.1079026478671
     [Google Scholar]
  78. HatamiB AshtariS SharifianA Rahmani SerajiH KhaliliE HatamiY ZaliMR Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients. Gastroenterol Hepatol Bed Bench.201710Suppl1S20S26
     [Google Scholar]
  79. AmirkalaliB. PoustchiH. KeyvaniH. KhansariM.R. AjdarkoshH. MaadiM. SohrabiM.R. ZamaniF. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran.Iran. J. Public Health20144391275128326175982
     [Google Scholar]
  80. YuanY. YangF. WangY. GuoY. Factors associated with liver cancer prognosis after hepatectomy.Medicine202110042e2737810.1097/MD.000000000002737834678864
     [Google Scholar]
  81. SiegelR.L. MillerK.D. JemalA. Cancer statistics, 2019.CA Cancer J. Clin.201969173410.3322/caac.2155130620402
     [Google Scholar]
  82. El-SeragH.B. Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology2012142612641273.e110.1053/j.gastro.2011.12.06122537432
     [Google Scholar]
  83. PiñerosM FrechS FrazierL LaversanneM BarnoyaJ GarridoC GharzouziE ChacónA Fuentes AlabiS Ruiz de CamposL FigueroaJ DominguezR RojasO PereiraR RiveraC MorganDR Advancing reliable data for cancer control in the central america four region.J Glob Oncol20184111
     [Google Scholar]
  84. XiaoJ. WangF. WongN.K. GaoB. WangH. LiC. Global liver disease burden and research trends: Analysis from a Chinese perspective. Public Health2019711212221
     [Google Scholar]
  85. PimpinL. Cortez-PintoH. NegroF. WebberL. SheronN. Burden of liver disesea in Europe: Epidimiology and analysis of risk factors to identify preventive policies.Seminar2018693718735
     [Google Scholar]
  86. BlachierM LeleuH Peck-RadosavljevisM VallaDCH Roudot-ThoravalF The burden of liver disease in Europe: A review of available epidemiological data. Journal of Hepatology201358359360810.1016/j.jhep.2012.12.005
     [Google Scholar]
  87. FerlayJ ParkinDM Steliarova-FoucherE Estimates of cancer incidence and mortality in Europe in 2008.Eur J Cancer201046756781
     [Google Scholar]
  88. López-VelázquezJ.A. Silva-VidalK.V. Ponciano-RodríguezG. Chávez-TapiaNC. ArreseM. MisaelUribe. Méndez-SánchezN. The prevalence of nonalcoholic Ascha fatty liver disease in the AmericasAnn Hepatol201432166178
     [Google Scholar]
  89. GuglielmiA. RuzzenenteA. ConciS. ValdegamberiA. VitaliM. BertuzzoF. De AngelisM. MantovaniG. IaconoC. Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations.World J. Gastroenterol.201420247525753310.3748/wjg.v20.i24.752524976693
     [Google Scholar]
  90. WellensteinM.D. de VisserK.E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape.Immunity201848339941610.1016/j.immuni.2018.03.00429562192
     [Google Scholar]
  91. DingJ. WenZ. Survival improvement and prognosis for hepatocellular carcinoma: Analysis of the SEER database.BMC Cancer2021211115710.1186/s12885‑021‑08904‑334715816
     [Google Scholar]
  92. AschaM.S. HanounehI.A. LopezR. TamimiT.A.R. FeldsteinA.F. ZeinN.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology20105161972197810.1002/hep.2352720209604
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882271605231211102803
Loading
Review of Hepatocellular Carcinoma and Liver Disease Prevalence
NEW Emirates Medical J 5, e02506882271605 (2024); https://doi.org/10.2174/0102506882271605231211102803
/content/journals/nemj/10.2174/0102506882271605231211102803
/content/journals/nemj/10.2174/0102506882271605231211102803
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cancer; Disease; Liver; Prevalence; Systematic review; Worldwide

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test